Key terms

About IART

Integra LifeSciences Holdings Corp. engages in the provision of regenerative tissue technologies and neurological solutions dedicated to limiting uncertainty for clinicians. It operates under the Codman Specialty Surgical (CSS) and Tissue Technologies (TT) segments. The CSS segment includes technologies and instrumentation used for neurosurgery, neurocritical care, and otolaryngology. The TT segment focuses on complex wound surgery, surgical reconstruction, and peripheral nerve repair. The company was founded by Richard E. Caruso in 1989 and is headquartered in Princeton, NJ.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest IART news

Mar 11 8:33am ET Integra LifeSciences launches MicroMatrix Flex Feb 29 7:41am ET Integra LifeSciences price target lowered to $42 from $45 at BofA Feb 29 7:22am ET Truist Financial Sticks to Their Hold Rating for Integra Lifesciences (IART) Feb 29 7:18am ET Integra LifeSciences price target lowered to $49 from $55 at JMP Securities Feb 29 6:52am ET BTIG Sticks to Its Hold Rating for Integra Lifesciences (IART) Feb 29 6:14am ET Integra LifeSciences price target lowered to $45 from $49 at Wells Fargo Feb 29 5:39am ET Buy Rating on Integra Lifesciences Amidst Recovery and Growth Prospects Feb 29 5:28am ET Integra Lifesciences: Sell Rating Justified by Underwhelming Financials and Leadership Concerns Feb 29 12:40am ET Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (MIRM) and Integra Lifesciences (IART) Feb 28 6:32am ET Integra Lifesciences Announces CEO Transition and New Executive Chairman Feb 28 6:09am ET Integra LifeSciences CEO Jan De Witte to retire by the end of 2024 Feb 28 6:08am ET Integra LifeSciences sees Q1 adjusted EPS 53c-57c, consensus 74c Feb 28 6:07am ET Integra LifeSciences sees FY24 adjusted EPS $3.15-$3.25, consensus $3.44 Feb 28 6:05am ET Integra LifeSciences reports Q4 adjusted EPS 89c, consensus 90c Feb 21 6:50pm ET Analysts Are Bullish on These Healthcare Stocks: Bausch + Lomb Corporation (BLCO), Integra Lifesciences (IART) Feb 06 8:07am ET Integra Lifesciences: A Strong Buy on FDA Approval and Re-launch Optimism Feb 06 5:39am ET Integra Lifesciences (IART) Receives Buy Rating Following FDA Approval of CereLink Monitors Jan 07 5:37am ET Integra Lifesciences (IART) Gets a Hold from BTIG Jan 02 10:01am ET Analysts Offer Insights on Healthcare Companies: Streamline Health Solutions (STRM), MiMedx Group (MDXG) and Integra Lifesciences (IART) Dec 31 5:16am ET BTIG Sticks to Its Hold Rating for Integra Lifesciences (IART) Dec 22 7:49am ET Integra LifeSciences price target raised to $46 from $44 at Truist Dec 14 7:22am ET Integra LifeSciences price target raised by $5 at Truist, here’s why Dec 13 8:50pm ET Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Alnylam Pharma (ALNY) and Integra Lifesciences (IART) Dec 13 4:55pm ET Integra Lifesciences: A Strong Buy on Strategic Acquisition and Promising Growth Trajectory Dec 13 7:58am ET Wells Fargo Keeps Their Buy Rating on Integra Lifesciences (IART) Dec 13 7:46am ET Integra Lifesciences (IART) Receives a Hold from BTIG Dec 13 6:17am ET Integra to acquire Acclarent from Johnson & Johnson for $275M

No recent news articles are available for IART

No recent press releases are available for IART

IART Financials

1-year income & revenue

Key terms

IART Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

IART Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms